Therefore, we hypothesized that tacrolimus would prevent alloantibody-induced glomerular lesions, in part via inhibition of vWF secretion from endothelial cells. Here, we used a human in vitro model of glomerular endothelium expressing HLA class I and II antigens and demonstrated that anti-HLA class II antibodies elicit a higher endothelial release of vWF than do anti-HLA class I antibodies in cell supernatants.
We observed that tacrolimus treatment decreased vWF secretion after stimulation with both classes of anti-HLA antibodies and decreased platelet adhesion on allostimulated endothelial cells in a microfluidic chamber. In kidney recipients, tacrolimus trough levels were negatively associated with vWF blood levels. These results indicate that direct disruption of hemostasis via vWF secretion is a potential mechanism of antibody-mediated injury in patients with DSAs. Our results further suggest that the targeting of microcirculation hemostasis may be beneficial to prevent the development of microangiopathic lesions in antibody-mediated rejection.
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alloantibody, basic (laboratory) research/science, immunosuppressant-calcineurin inhibitor: tacrolimus, kidney transplantation/nephrology, rejection: antibody-mediated (ABMR), translational research/science Data suggest that one of the pathogenic mechanisms of anti-HLA antibodies is the disruption of hemostasis. Notably, it has been reported that anti-HLA class I antibodies (anti-HLA-I) promote vWF secretion and lead to vascular inflammation and microthrombosis. 7, 8 von Willebrand factor (vWF) is stored in cytoplasmic organelles named Weibel-Palade bodies (WPB). The primary role of vWF is the formation of an adhesive extracellular matrix via the release of long multimers from endothelial cells, which allows in situ platelet aggregation and microangiopathy. 9 Endothelial cells are responsible for most of the vWF multimers found in the blood. 10 Calcineurin inhibitors (CNIs) interact with high-affinity binding proteins, termed immunophilins, which are ubiquitous. 11 In addition to their known effects on lymphocytes, they block pathways in other cell types, such as endothelial cells. 12 Clinically, CNI-sparing therapeutic regimens result in higher rejection rates. 13, 14 We recently reported that low CNI levels in kidney transplant recipients with de novo DSAs were associated with graft loss. 15 This effect may be due to a direct effect of CNIs on B cell activation, 16 but no clear mechanism fully explains this clinical observation, especially because these drugs likely do not reverse the plasma cell secretion of antibodies.
We tested the hypothesis that CNIs are beneficial to patients with de novo DSAs via direct action on the hemostasis, specifically inhibition of vWF secretion by endothelial cells after allostimulation.
The in vitro findings prompted us to examine whether a relationship existed between tacrolimus blood levels and vWF levels in the sera of kidney recipients.
| MATERIAL AND ME THODS

| Endothelial cell cultures
| Microvascular endothelial cell lines
Endothelial cells were cultured as described previously. 6 Briefly, primary human glomerular microvascular endothelial cells (GMVECs;
Cell Systems, Kirkland, WA) and primary human renal glomerular endothelial cells (HRGECs; ScienCell, San Diego, CA) were grown to confluence before use. Cells were obtained at passage 3 by the manufacturer and used at passages 4 and 5 in the experiments.
| Stimulation of endothelial cells with anti-HLA antibodies
Mouse IgG2a anti-human monoclonal HLA class I antibody clone W6/32 (Sigma-Aldrich, St Louis, MO), mouse IgG2a anti-human monoclonal HLA-DR, DP, DQ clone Tü39 (BD Biosciences, San Diego, CA), and clone WR18 (ThermoFisher Scientific, Rockford, IL) at 1 or 2 μg/mL were used to stimulate endothelial cells for 10 minutes or 1 hour. The concentrations of anti-HLA antibodies used are the expected physiological concentrations in human blood, as measured after the purification of DSAs from patients using specific immunoaffinity columns. 17 Stimulation with histamine (Prepotech, Rocky Hill, NJ) at 1.0 mmol/L for 10 minutes or thrombin at 1 U/mL (ThermoFisher Scientific) for 1 hour was used as a positive control. Tacrolimus was obtained from Enzo Life Sciences Inc. (Farmingdale, NY). Assessment of cell viability and the methods used to test cyclosporine, prednisone, and mycophenolic acid are described as Supplemental Material.
| Fluorescent microscopy and cell measurements
Immunostaining was performed as described previously using a goat anti-human vWF (Bethyl, Montgomery, TX) primary antibody. 6 Additional details are available as Supplemental Material.
| Platelet preparation and adhesion assay
Human blood was drawn from healthy donors into ACD tubes (acid citrate dextrose additives; BD Biosciences), and platelets were prepared as described previously. 18 Platelets under static conditions and platelet strings under flow were measured manually by using CellSens Olympus software (Olympus, Tokyo, Japan). 10 fields were averaged for each condition. Additional details are available as Supplemental Material. 
| ELISA of cell supernatants and serum
| Patients and sera
Patient recruitment, biopsy grading, and screening for circulating anti-HLA antibodies were described previously. 6 In all cases, the biopsies reported were indication biopsies. This protocol was approved by the institutional ethics committee (#2017-3048). All participants gave written informed consent. The activities being reported are consistent with the Principles of the Declaration of Istanbul.
| Statistical analysis
vWF levels between groups were compared by using, first, a 1-way ANOVA, followed, when the ANOVA was significant, by the MannWhitney U test or unpaired t-test as appropriate. Linear regression models were used to examine the association between tacrolimus and vWF levels. Statistical analyses were performed by using SPSS Statistics version 23 (IBM, Armonk, NY). All tests were 2-tailed, and a value of P < .05 was considered significant.
| RE SULTS
| vWF secretion from glomerular endothelial cells after anti-HLA-I and -II stimulation
We first examined the effects of anti-HLA antibodies on the production of vWF strings on GMVECs without exposure to tacrolimus. In all conditions, endothelial cells were first treated with interferon-γ for 48 hours to induce HLA-II antigen expression on the cell surface. 6 GMVECs were incubated with an anti-HLA-I or anti-HLA class II antibody (anti-HLA-II, 1 or 2 μg/mL) for 10 minutes. 7, 19 GMVECs were stained after treatment to examine the surface expression of vWF strings using immunofluorescence ( Figure 1 ). First, we 
| vWF secretion from glomerular endothelial cells after patients' sera stimulation
Next, we typed the endothelial cells and examined the effect of sera from patients with confirmed anti-HLA circulating antibodies corresponding to equivalent of "DSAs" to the endothelial cells (Table S1 ) and used sera from patients without anti-HLA antibodies as controls. Stimulation with both types of sera resulted in a significant increase in the percentage of vWF-positive cells ( Figure 2 and Figure S3 ). In addition, we observed a higher expression of vWF in the "DSAs" compared with the "no DSAs" group of stimulations.
| Effect of tacrolimus treatment on vWF secretion from GMVECs after anti-HLA stimulation
To investigate the effect of tacrolimus on vWF release, we repeated the same cell culture protocol, but we preincubated endothe- We also measured soluble vWF levels in the supernatants.
Both concentrations of tacrolimus substantially decreased these levels ( Figure 3D ). vWF levels were also significantly lower when histamine-treated cells were exposed to tacrolimus. Considered to-
gether, these data demonstrate that pharmacological doses of tacrolimus abrogated the surface expression and the secretion of vWF by
GMVECs stimulated with anti-HLA antibodies.
Finally, we tested the effects of cyclosporine, prednisone, and mycophenolic acid on anti-HLA-stimulated GMVECs. We found a significant decrease after cyclosporine treatment ( Figure 4A ), whereas prednisone and mycophenolic acid had no effect on vWF expression ( Figure 4B,C) .
| Platelet adhesion after tacrolimus treatment and anti-HLA stimulation
Next, we assessed the functional impact of tacrolimus on anti-HLA-mediated endothelial exocytosis. We cultured GMVECs using the same culture protocol just described and measured the adhe- Figure 5D ).
F I G U R E 2 Expression of membrane von Willebrand factor
(vWF) after stimulation with sera from transplant recipients of glomerular microvascular endothelial cells (GMVECs) for 10 minutes. Cells with vWF strings were counted manually using cellSens software by 2 persons who were blinded to treatment. vWF expression between stimulation with sera with anti-HLA DSAs or without, n = 3-5. Bars represent mean ± SEM. *P < .05. NS, nonstimulated cells
F I G U R E 3 Expression of von
Willebrand factor (vWF) following 30 minutes of preincubation with tacrolimus. A, B. Cells were labeled using goat antihuman vWF IgG and rabbit anti-goat IgG-Alexa Fluor 488 to detect vWF strings. Nuclei were stained blue with 4′,6-diamidino-2-phenylindole (DAPI), and actin was stained red with phalloïdin. The cells were fixed in 4% paraformaldehyde before labeling. GMVECs were at passage 4. Illustrative photomicrographs taken with an Olympus IX83 (×40 for all panels) equipped with an Olympus DP80 camera and acquired using cellSens software. n = 7. C. Percentage of cells positive for vWF were counted manually. n = 7. D. vWF concentrations were measured using ELISA. Bars represent mean ± SEM. n = 7. **P < .01. NS, nonstimulated cells; T0, no tacrolimus; T5, tacrolimus 5 ng/mL; T10, tacrolimus 10 ng/mL; Hist, histamine 
| Serum vWF in kidney transplant recipients with tacrolimus
We used sera from kidney recipients with stable graft function and stable medical condition to elucidate the relationship between tacrolimus exposure and vWF release in patients. None of these patients exhibited DSAs. vWF blood levels were measured by using an ELISA.
Clinical data in this cohort, including tacrolimus blood levels and immunosuppressive medication doses, were prospectively recorded at the time of the blood draw. Seventy-one samples from 69 patients were available. First, we used a simple linear regression model and found a strong negative association between tacrolimus and vWF blood levels (β = −768 ± 239 ng/mL vWF for each increase in 1 ng/mL tacrolimus, P = .002; Table 2 , Model A). Second, we assessed whether tacrolimus level remained a significant predictor of vWF levels after adjustment for baseline clinical covariates, the doses of prednisone and mycophenolate, and platelet count. The association persisted after this adjustment, with a coefficient of similar magnitude as the unadjusted analysis (β = −643 ± 230 ng/mL, P = .007; biopsy on the same day that blood was collected for vWF measurement, and these patients were included in the analysis. Tacrolimus was also associated with vWF levels to a similar magnitude in this model (β = −863 ± 337 ng/mL, P = .014; Table 2 , Model C), but none of the histological scores were significant.
Next, we validated these observations in a smaller cohort of kidney recipients with proven circulating de novo DSAs; 26 samples from 20 patients were available (Table S2 and Figure S6 ).
In the unadjusted model, we observed an association of higher magnitude between tacrolimus and vWF compared with the cohort described earlier (β = −1337 ± 425 ng/mL, P = .004; Table 2 , Model A). The model adjusted for the clinical covariates showed a similar association (β = −1154 ± 529 ng/mL, P = .042; Table 2 , Model B). Adjustment for histological covariates was conducted on 20 samples because the patient with multiple sera underwent biopsy at just 1 time point; here, we found a consistent association, with a trend toward significance (β = −900 ± 514 ng/mL, P = .119; Table 2 , Model C). Collectively, these data indicate that higher tacrolimus blood levels were associated with lower vWF levels in the sera of kidney recipients with and without DSAs.
| D ISCUSS I ON
In this study, we found that anti-HLA-I and -II antibodies exert differential effects on vWF secretion in human glomerular endothelial cells. We also demonstrated that tacrolimus inhibits the release of vWF from these cells and significantly decreases platelet adhesion after anti-HLA stimulation. We demonstrated the same effect after treatment with cyclosporine. In support with these in vitro observations, we observed a negative relationship between tacrolimus trough levels and vWF levels in the sera of kidney recipients.
Overall, these data provide new insight into the poorer outcomes F I G U R E 4 Expression of von Willebrand factor (vWF) following 30 minutes of preincubation with several immunosuppressive agent. A. Incubation with cyclosporine. Cells were labeled using goat anti-human vWF IgG and rabbit anti-goat IgG-Alexa Fluor 488 to detect vWF strings. Nuclei were stained blue with 4',6-diamidino-2-phenylindole (DAPI) and actin was stained red with phalloïdin. The cells were fixed in 4% paraformaldehyde prior to labeling. GMVECs were at passage 4. Illustrative photomicrographs taken on an Olympus IX83 (×40 for all panels) equipped with an Olympus DP80 camera and acquired using cellSens software. B. Incubation with prednisone. C. Incubation with mycophenolic acid. Bars represent mean ± SEM. n = 3. *, P < .05. NS, nonstimulated cells; Hist, histamine; C0;300;600, cyclosporine concentrations in ng/mL; P0;5;10, prednisone concentrations in ng/mL; M0;5;10, mycophenolic acid concentrations in μg/mL The differential effect noted between anti-HLA-I and anti-HLA-II on vWF has not been reported before and is in line with recent observations that we made on the expression of thrombomodulin in
GMVECs treated with anti-HLA antibodies. 6 Thrombomodulin has an anticoagulant role on the endothelial surface. We found that whereas anti-HLA-I promotes the release of thrombomodulin, anti-HLA-II leads to an absence of expression. Collectively, these results suggest that anti-HLA-II exerts a prothrombotic effect on endothelial cells, promoting the microangiopathic lesions seen in TG.
A recent study involving HUVECs identified the annexin A2-S100-A10 complex as a component of the cyclic adenosine monophosphate (cAMP)-dependent pathway of vWF secretion that is blocked by cyclosporine. 26 Two main pathways are involved in the exocytosis of WPB content, which require an increase in cytosolic Ca 2+ or cAMP levels. 9, 26 Brandherm et al demonstrated that cyclosporine prevents the dephosphorylation of annexin A2 and impedes the formation of a heterotetramer with S100-A10, 26 which is an essential protein to priming the fusion of the WPB to the cellular membrane. Data in yeast support the finding that tacrolimus have a direct impact on GTPases, notably those involved in membrane trafficking. 27 Interestingly, this mechanism is reminiscent of the direct effect of CNIs on podocytes. 28 In podocytes, cyclosporine acts on effectors of GTPases such as synaptopodin, which stabilizes the actin cytoskeleton. 28 Additional experiments are under way to fully elucidate the role of alloantibodies and tacrolimus on this secretion pathway.
There are some limitations to the present study. The data were Data are provided as the mean ± SD or n (% 29 and its severity is not related to blood levels. It has been elucidated that this toxicity is related to the inhibition of prostacyclin synthesis in endothelial cells. 23, 30 In summary, this study demonstrates that tacrolimus may pre- The β coefficient corresponds to the variation in vWF level (ng/mL) for each increase in 1 ng/mL of tacrolimus trough level, as estimated by linear regression models. Biopsy scores are provided according to the Banff classification (scores 0-3): t, tubulitis; i, interstitial inflammation; v, intimal arteritis; g, glomerulitis; ptc, peritubular capillaritis; C4d, staining for the C4d component of the complement; ct, tubular atrophy; ci, interstitial fibrosis; cv, fibrous intimal thickening; cg, allograft glomerulopathy. a n = 71 samples from 71 patients. b n = 26 samples from 20 patients. c Mycophenolate mofetil equivalents. d For stable patients n = 58; this number is different than in models A and B because some patients did not have a biopsy at the time the blood was drawn.
TA B L E 2 Relationship between tacrolimus trough levels and vWF blood levels
